SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical tensions, primarily fueled by President Trump's recent rhetoric regarding Greenland and threats of substantial tariffs against European allies like France. The community is bracing for significant market volatility, with many predicting a "bloodbath" and actively discussing bearish positions, while others anticipate a "buy the dip" recovery. These concerns are amplified by broader instability in global financial markets, including surging bond yields in both the US and Japan.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid escalating geopolitical tensions and tariff threats from the US concerning Greenland, compounded by an anticipated Supreme Court decision related to tariffs, which has triggered a pre-market sell-off in tech-heavy indices. Community sentiment is sharply divided; while some anticipate a severe market downturn and "Black Tuesday," many others see this as a manufactured dip and a "buy the dip" opportunity, expecting a quick recovery. This dynamic reflects QQQ's sensitivity to global trade policy and broader economic uncertainties, despite ongoing tech sector narratives.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as its Anktiva therapy receives broad international approval for lung and other cancers, drawing immense community discussion around its potential to revolutionize oncology. Investors are actively debating a substantial short squeeze and a paradigm shift in cancer treatment, fueled by the company's innovative immunotherapy platform and recent commercial momentum. The conversation highlights the global impact of this therapeutic approach and calls for broader regulatory recognition.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing strong bullish momentum following its presentation of breakthrough pancreatic cancer trial data at the JPM Healthcare Conference, where its Alpha DaRT technology's unique immune-preserving properties garnered significant attention. The community is actively discussing the stock, fueled by widespread anticipation of imminent Japanese regulatory approval and whispers of institutional buying. This positions the innovative oncology treatment for a potential re-rating as awareness of its revolutionary potential grows.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is heavily discussed due to its strong pivot towards becoming a major AI cloud infrastructure provider, significantly highlighted by a massive power and infrastructure deal with a prominent tech client. Community sentiment points to high expectations for additional large-scale AI/HPC partnerships, particularly given its substantial power capacity and strategic advantages in the booming compute sector. Investors are actively watching for further developments as the company solidifies its position beyond traditional crypto mining.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is actively trending, fueled by its aggressive expansion in the artificial intelligence sector, notably a new data center lease deal with RIOT Platforms to support significant AI workload capacity. The community is discussing AMD's strengthened position as a leading contender in high-performance AI, reinforced by analyst upgrades, including Wells Fargo naming it a top pick for 2026. This reflects broader market optimism around insatiable demand for data center computing, where AMD is carving out substantial growth.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending after its recent AGM, where a significant increase in authorized shares passed alongside the announcement of a $200 million investment in MrBeast Industries. This has fueled a polarized community discussion, with concerns over potential dilution and the company's strategic direction clashing against long-term bullish sentiment for its Ethereum treasury holdings. The controversy leaves many questioning the immediate impact on BMNR's perceived connection to Ethereum's performance.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following its Investor Day, where the company announced significantly raised revenue guidance for 2026 and a substantial increase in its backlog, alongside a billion-dollar offering that reflects strong institutional confidence in its strategic defense technology acquisitions. The community is sharply divided, with bulls emphasizing the firm's combat-proven drone and counter-UAS capabilities for future growth, while others express concern over stock volatility and valuation, leading to a mixed market reaction to its updated outlook.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors are enthusiastic about recent confirmations of its Optical Interposer technology being utilized by major players like Marvell, acquired through Celestial AI. The community is actively discussing POET's role as a critical enabler for the AI and data center "optical supercycle" by offering high-density, low-power, and cost-effective optical interconnect solutions. Anticipation is high for upcoming customer and investor disclosures, though some perceive market manipulation hindering immediate price appreciation.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to impressive preliminary business results, a significantly accelerated revenue outlook for its products, and a major patent extension for IBSRELA and XPHOZAH through 2041. The community is particularly excited about IBSRELA's updated projection to reach $1 billion in annual revenue by 2029, much earlier than previously anticipated. This extended intellectual property protection is seen as a "game changer" by many, leading to multiple analyst upgrades and discussions about substantial long-term value and increased acquisition potential for the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday...

TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know

TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Recommendation of "Hold" from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat...

TriSalus Life Sciences (NASDAQ:TLSI) Given New $12.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday...

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Moderate Buy" by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat...

TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Friday...

FY2026 EPS Estimates for TLSI Increased by Cantor Fitzgerald

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2026 earnings estimates for shares of TriSalus Life Sciences in a research note...

TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery

TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the...

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.14	--	--	N/A
Q3 '25	-$0.15	-$0.96	-546.03%	MISSED
Q2 '25	-$0.21	-$0.27	-30.19%	MISSED
Q1 '25	-$0.22	-$0.39	-77.56%	MISSED
Q4 '24	-$0.32	-$0.40	-26.02%	MISSED

TLSI
TriSalus Life Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TLSI News

TLSITriSalus Life Sciences Inc